Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a biopharmaceutical company focused on developing and commercializing therapies for unmet medical needs, has been navigating a complex landscape of ...
Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...
Vanda Pharmaceuticals Inc (VNDA) reports strong Fanapt sales growth and strategic initiatives, despite facing increased ...
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
M, consensus $284.9M Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and ...
For the psychiatry portfolio alone, Vanda is targeting annual revenue in excess of $750M in 2030, assuming the potential approval of Bysanti ...
Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total ...
Vanda Pharmaceuticals emphasized its strategic focus on expanding its psychiatry portfolio through the launches of Fanapt in bipolar I disorder and the anticipated approvals for Bysanti and Fanapt ...
WASHINGTON (AP) — WASHINGTON (AP) — Vanda Pharmaceuticals Inc. (VNDA) on Thursday reported a loss of $4.9 million in its fourth quarter. On a per-share basis, the Washington-based company said it had ...
Kevin Moran; Chief Financial Officer, Senior Vice President, Treasurer; Vanda Pharmaceuticals Inc Mihael Polymeropoulos; Chairman of the Board, President, Chief Executive Officer; Vanda ...
Hello, and thank you for standing by. At this time, I would like to welcome you to the Q4 2024 Vanda Pharmaceuticals, Inc. Earnings Conference Call. [Operator Instructions] I would now like to ...